Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs supplies extensive anti-EIIIB CART products and services to support CART development for global customers. Our technical team is very pleased to receive any inquiry about CART development, please do not hesitate to contact us.
EIIIB is a fibronectin spliced variant that is strongly expressed in tumor stroma and neovasculature, but not in many normal tissues. Several studies showed that increased extracellular matrix (ECM) deposition is one of the important features of cancer, fibrosis, and inflammatory diseases. EIIIB serves as an important ECM marker, making it an attractive target for imaging and therapeutic approaches. EIIIB-CAR-T cells have been developed to treat tumors and regulate TME.
Fig.1 Schematic representation of EIIIB Expression at the tumors and metastatic sites by H&E staining and IHC using EIIIB antibody clone NJB2.1
Pancreatic ductal adenocarcinoma
Fibrosis
Inflammatory disorders
Others
Anti-EIIIB CAR-T Expression Test
CAR expression detection by flow cytometry using recombinant antigen protein is an effective means of CAR test, which is convenient and easy to operate for CART development. Creative Biolabs has developed various kinds of CAR detection reagents to support CAR expression tests, including antigen-specific antigen protein with sensitive fluorescence and CAR linker detection reagents. Meanwhile, we supply several appropriate and robust methods for CAR expression detection, such as qPCR, WB, and Flow cytometry.
Fig.2 CAR expression test of Anti-EIIIB fibronectin-targeted CAR T cells by flow cytometry. Anti-EIIIB CART cells were incubated with recombinant EIIIB-GST and detected by rabbit anti-GST and anti-rabbit A647 secondary antibody.2
Anti-EIIIB CAR-T In Vitro Cytotoxicity Assay
EIIIB-specific CAR T cells (B2 CAR) exhibited increased cytotoxicity against aortic endothelial cells (FN+/+) at the specific E:T ratio. At Creative Biolabs, we offer optimized cytotoxicity assay services to validate the specificity and cytotoxicity of CART cells to speed up global customers’ projects.
Fig.3 In vitro cytotoxicity assay of anti-EIIIB CAR-T (B2 CAR) against aortic endothelial cells (AEC) expressing the EIIIB fibronectin domain (FN+/+) at the indicated E:T ratio.2
In addition, we are dedicated to providing a wide range of in vitro test for CART development, including but not limited to:
Anti-EIIIB CAR-T Cytokine Release Test
Anti-EIIIB CAR-T Cell Proliferation Assay
Anti-EIIIB CAR-T Cell Phenotype Analysis
Efficacy Test of Anti-EIIIB CAR-T
To test the degree of efficacy of CAR T cells against tumors, we have established an extensive range of animal models to conduct efficacy validation. According to the characteristics of different targets, we designed optimized animal experiments to further detect the in vivo efficacy of CART cells.
Fig.4 In vivo efficacy test of EIIIB CAR-T cells against B16 bearing-tumor. (A) Schematic diagram of in vivo mouse model for EIIIB CAR-T evaluation. (B) The tumor area measurement of in vivo model treated with CART cells.2
Toxicity Evaluation Anti-EIIIB CAR-T
To more closely analyze the mechanisms of efficacy and toxicity of CART cells, Creative Biolabs specializes in offering a variety of toxicological evaluation services to aid in CART development, including but not limited to off-target toxicity analysis, tumorigenicity studies, etc.
Immune Infiltration Test of Anti-EIIIB CAR-T
Fig.5 Necrotic analysis of tumors samples from mouse model treated with EIIIB CAR T cells to test immune infiltration.2
Immunogenicity Analysis of Anti-EIIIB CAR-T
Fig.6 Anti-EIIIB clone B2 response of serum from B16-bearing WT mice treated with EIIIB CAR-T to test immunogenicity.2
References
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-0120ZP231 | Anti-EIIIB (XHM156) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | XHM156 | Human | scFv-CD28-CD118ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP232 | Anti-EIIIB (XHM156) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | XHM156 | Human | scFv-4-1BB-CD118ζ | Lentiviral vector | T Cell | ||
| XS-0622-ZP3308 | Anti-EIIIB h(VHH1-VHH2-CD28-CD3ζ) Biepitopic CAR, pCDCAR1 | Human | VHH1-VHH2-CD28-CD3ζ | Lentiviral vector | T Cell | ||||
| XS-0622-ZP3480 | Anti-EIIIB h(VHH1-VHH2-4-1BB-CD3ζ) Biepitopic CAR, pCDCAR1 | VHH1-VHH2-4-1BB-CD3ζ | Lentiviral vector | T Cell | |||||
| XS-0822-YF339 | Anti-Human EIIIB (XW-339) h(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-339 | Mouse | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF1259 | Anti-Human EIIIB (XW-339) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-339 | Mouse | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF2179 | Anti-Human EIIIB (XW-339) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-339 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF8685 | TS-Fluc Anti-Human EIIIB scFv (XW-339) CD28-CD3ζ CAR, pCDCAR1 | Human | XW-339 | Mouse | 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9094 | TS-Fluc Anti-Human EIIIB scFv (XW-339) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-339 | Mouse | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9503 | TS-Fluc Anti-Human EIIIB scFv (XW-339) CD28-41BB-CD3ζ CAR, pCDCAR1 | Human | XW-339 | Mouse | 7H-YB-Fluc-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9912 | TS-IL15 SA Anti-Human EIIIB scFv (XW-339) CD28-CD3ζ CAR, pCDCAR1 | Human | XW-339 | Mouse | 7H-YB-IL15 SA-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | |||
| XS-0822-YF10321 | TS-IL15 SA Anti-Human EIIIB scFv (XW-339) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-339 | Mouse | 7H-YB-IL15 SA-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF10730 | TS-IL15 SA Anti-Human EIIIB scFv (XW-339) CD28-41BB-CD3ζ CAR, pCDCAR1 | Human | XW-339 | Mouse | 7H-YB-IL15 SA-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
| XS-1122-YF1259 | Anti-EIIIB TCR-ABR (scFv-TCRα, XW-339) CAR Plasmid, pCDCAR1 | Human | XW-339 | Mouse | scFv-TCRα | Lentiviral vector | T Cell | ||
| XS-1122-YF2179 | Anti-EIIIB TCR-ABR (scFv-TCRβ, XW-339) CAR Plasmid, pCDCAR1 | Human | XW-339 | Mouse | scFv-TCRβ | Lentiviral vector | T Cell | ||
| XS-1122-YF3099 | Anti-EIIIB TCR-ABR (scFv-CD3γ, XW-339) CAR Plasmid, pCDCAR1 | Human | XW-339 | Mouse | scFv-CD3γ | Lentiviral vector | T Cell | ||
| XS-1122-YF4019 | Anti-EIIIB TCR-ABR (scFv-CD3δ, XW-339) CAR Plasmid, pCDCAR1 | Human | XW-339 | Mouse | scFv-CD3δ | Lentiviral vector | T Cell | ||
| XS-0123-ZP629 | Anti-EIIIB (B2) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | B2 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0323-ZP629 | Anti-EIIIB (B2 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | B2 | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0923-LX53 | Anti-hEIIIB (CD28-41BB-CD3ζ) CAR-duplex CTLA4 pCDCAR1 Vector | Human | X9X-22 | scFv-CD28-41BB-CD3ζ-duplex CTLA4 | Lentiviral vector | T cell | CAR-T |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
